Shuttle Pharmaceuticals Holdings Inc (SHPH)

$2.32 +0.01 (0.43%)
Market Cap 2.47M
Revenue (ttm) 0.00
Net Income (ttm) -9.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 49,200
Avg Vol 275,882
Day's Range N/A - N/A
Shares Out 1.07M
Stochastic %K 11%
Beta -1.01
Analysts Strong Buy
Price Target N/A

Company Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HD...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 403 4212
Address:
401 Professional Drive, Suite 260, Gaithersburg, United States
chapelp
chapelp Nov. 7 at 4:56 PM
$SHPH look at the f@king manipulation , there are no buyers agree , but there are no sellers either , so only MOTHERF@KER SHORTS swapping their naked fake shares to drop the price hoping for retail to give up !!!
1 · Reply
samir268
samir268 Nov. 6 at 5:26 PM
$SHPH piece of shit/garbage. Management sucks
0 · Reply
chapelp
chapelp Nov. 6 at 5:21 PM
$SHPH any explanation for loosing half of its value in just 3 weeks ?!
1 · Reply
jmk8888
jmk8888 Nov. 6 at 5:15 PM
$SHPH please send an email to mailto:[email protected] and mailto:[email protected] to express your concerns on how management is not protecting our value.
0 · Reply
SylvanEmperor
SylvanEmperor Nov. 6 at 1:19 PM
$SHPH ok. Should get interesting
1 · Reply
chapelp
chapelp Nov. 5 at 9:05 PM
$SHPH 3 mil volume or 80k ... same bulls#it ... motherf@kers are manipulating either way and the f@king management doesn't care as long as they get their funds outside the markets !!!
0 · Reply
thePEEPSchamp
thePEEPSchamp Nov. 4 at 4:26 PM
$SHPH shake out
0 · Reply
jaynamb
jaynamb Nov. 3 at 6:43 PM
$SHPH where are we heading?
1 · Reply
iveyoil
iveyoil Nov. 3 at 4:11 PM
$SHPH Long at 3.14. Why would they price a placement above the market price??
2 · Reply
_www_larval_com_
_www_larval_com_ Nov. 3 at 3:38 PM
$SHPH just turned -3% lower to 8% (~3Mv) in the last few minutes, follow for more volatility.
0 · Reply
Latest News on SHPH
Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Nov 3, 2025, 7:00 AM EST - 12 days ago

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Oct 22, 2025, 10:00 AM EDT - 24 days ago

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Oct 22, 2025, 7:00 AM EDT - 24 days ago

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Oct 21, 2025, 5:55 PM EDT - 24 days ago

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Oct 21, 2025, 4:05 PM EDT - 24 days ago

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Shuttle Executes LOI with Molecule.ai

Oct 10, 2025, 10:20 AM EDT - 5 weeks ago

Shuttle Executes LOI with Molecule.ai

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Oct 9, 2025, 4:15 PM EDT - 5 weeks ago

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Aug 14, 2025, 4:05 PM EDT - 3 months ago

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Jun 24, 2025, 4:10 PM EDT - 5 months ago

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Jun 20, 2025, 3:55 PM EDT - 5 months ago

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Jun 12, 2025, 12:00 PM EDT - 5 months ago

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Jun 12, 2025, 8:30 AM EDT - 5 months ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Jun 4, 2025, 4:01 PM EDT - 5 months ago

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Shuttle Pharma Provides Corporate Update

May 15, 2025, 4:45 PM EDT - 6 months ago

Shuttle Pharma Provides Corporate Update

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

May 8, 2025, 4:01 PM EDT - 6 months ago

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 21, 2025, 4:15 PM EDT - 7 months ago

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Apr 10, 2025, 4:01 PM EDT - 7 months ago

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Mar 13, 2025, 4:10 PM EDT - 8 months ago

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Mar 12, 2025, 9:24 AM EDT - 8 months ago

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Mar 12, 2025, 6:20 AM EDT - 8 months ago

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Feb 26, 2025, 10:45 AM EST - 9 months ago

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 7, 2025, 9:00 AM EST - 11 months ago

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Nov 26, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Nov 13, 2024, 5:00 PM EST - 1 year ago

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 29, 2024, 9:05 PM EDT - 1 year ago

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 28, 2024, 4:05 PM EDT - 1 year ago

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 16, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Sep 4, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 26, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Aug 14, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Jun 18, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 22, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Shuttle Pharma Provides First Quarter 2024 Corporate Update

May 14, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 23, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Apr 3, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Mar 22, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Mar 5, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Feb 13, 2024, 8:00 AM EST - 1 year ago

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 23, 2024, 4:30 PM EST - 1 year ago

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 8, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Dec 11, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Nov 30, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Nov 14, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Sep 25, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

Sep 13, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

Sep 11, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

chapelp
chapelp Nov. 7 at 4:56 PM
$SHPH look at the f@king manipulation , there are no buyers agree , but there are no sellers either , so only MOTHERF@KER SHORTS swapping their naked fake shares to drop the price hoping for retail to give up !!!
1 · Reply
samir268
samir268 Nov. 6 at 5:26 PM
$SHPH piece of shit/garbage. Management sucks
0 · Reply
chapelp
chapelp Nov. 6 at 5:21 PM
$SHPH any explanation for loosing half of its value in just 3 weeks ?!
1 · Reply
jmk8888
jmk8888 Nov. 6 at 5:15 PM
$SHPH please send an email to mailto:[email protected] and mailto:[email protected] to express your concerns on how management is not protecting our value.
0 · Reply
SylvanEmperor
SylvanEmperor Nov. 6 at 1:19 PM
$SHPH ok. Should get interesting
1 · Reply
chapelp
chapelp Nov. 5 at 9:05 PM
$SHPH 3 mil volume or 80k ... same bulls#it ... motherf@kers are manipulating either way and the f@king management doesn't care as long as they get their funds outside the markets !!!
0 · Reply
thePEEPSchamp
thePEEPSchamp Nov. 4 at 4:26 PM
$SHPH shake out
0 · Reply
jaynamb
jaynamb Nov. 3 at 6:43 PM
$SHPH where are we heading?
1 · Reply
iveyoil
iveyoil Nov. 3 at 4:11 PM
$SHPH Long at 3.14. Why would they price a placement above the market price??
2 · Reply
_www_larval_com_
_www_larval_com_ Nov. 3 at 3:38 PM
$SHPH just turned -3% lower to 8% (~3Mv) in the last few minutes, follow for more volatility.
0 · Reply
Coney
Coney Nov. 3 at 3:33 PM
$SHPH holding up well in a red market
0 · Reply
Nova_Trades
Nova_Trades Nov. 3 at 2:55 PM
$SHPH starting to curl up — momentum building, could see a breakout soon.
0 · Reply
squiggleburp
squiggleburp Nov. 3 at 2:48 PM
$SHPH is this a hole in one or a hole? Dunno but I bought some. DOC?
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 3 at 2:36 PM
$SHPH curling
0 · Reply
Nova_Trades
Nova_Trades Nov. 3 at 1:58 PM
$SHPH — super thin. Keep it on watch, could move fast once volume hits.
0 · Reply
All_N_1986
All_N_1986 Nov. 3 at 1:54 PM
$SHPH if you think the SEC rules are there to help the little guys like us you are very mistaken 🤣
0 · Reply
chapelp
chapelp Nov. 3 at 1:42 PM
$SHPH government shutdown...SEC sleeping... Criminals thrive , over 2 millions shares sold premarket up to $4.8 and as soon as market opens, here we are .... Unf@kingbelivable
0 · Reply
Coney
Coney Nov. 3 at 1:39 PM
$SHPH in at $3.02… news is good and low float
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 3 at 1:35 PM
$SHPH thin keep eye
0 · Reply
TA_Kongen
TA_Kongen Nov. 3 at 1:23 PM
$SHPH Thin as ever. Watching.
0 · Reply
PaulVoice
PaulVoice Nov. 3 at 12:28 PM
$SHPH nothing too lose here. Ride it
1 · Reply
makedatbread88
makedatbread88 Nov. 3 at 12:16 PM
$SHPH 1M float good news
0 · Reply